The original success of Sildenafil undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Despite early returns were significant, the end of patents and the appearance of cheaper alternatives have diminished the customer base. Thus, a thorough assessment